# A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

> **NCT05702177** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Daridorexant 25 mg
- **DRUG:** Daridorexant 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05702177
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-05
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702177, "A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05702177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*